To identify molecular determinants of lymph node metastasis (LNM) in papillary thyroid carcinoma (PTC) focusing on mitochondrial metabolic reprogramming and immune evasion, highlighting their significance in metastasis.
Key Findings:
Identification of a high-risk 'Mito-high' subtype characterized by distinct metabolic reprogramming and an immunosuppressive microenvironment.
MGST1 was prioritized as a core predictor of LNM, achieving an AUC of 0.833 in external validation, as per the study's findings.
Pharmacological inhibition of MGST1 with Toxoflavin suppressed proliferation, migration, and invasion while inducing apoptosis, as demonstrated in the study.
Interpretation:
The study links MGST1 to mitochondrial metabolic reprogramming and immune evasion in PTC, suggesting its potential role in metastatic risk stratification.
Limitations:
The study's findings are based on retrospective data and may require further validation in prospective studies.
Potential confounding factors in the clinical cohort, such as BRAF mutation status and extrathyroidal extension, may affect the generalizability of the results.
Conclusion:
The study identifies MGST1 as a metabolic-immune regulator in PTC, with implications for further research into its role in high-risk patients.
